We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mylan may move forward with its proposed hostile takeover bid of Perrigo, as long as it divests seven generic drugs, the FTC has determined. The move is the final regulatory hurdle for Mylan’s bid and eases the FTC’s concerns that the deal would harm competition. Read More
A new EvaluatePharma report projects the orphan drug market will surge over the next five years, doubling the yearly growth of the overall prescription drug market. Read More
Valeant is offering patients access to its dermatology products for zero dollar copay under a program through major pharmacy chains and independent pharmacies. Read More
Continuing its string of proposed buyouts in the rare disease arena, Shire Pharmaceuticals is looking to snap up Massachusetts biotech Dyax in a deal worth up to $6.5 billion. Read More
Pharmaceutical industry watchers are saying that the Warner Chilcott kickback scandal may not single-handedly reshape the drug promotional landscape … but it’ll make one helluva dent. Read More
Hospira is voluntarily recalling more than 24,000 syringes of the injectable Amidate because out-of-specification results for degraded product were confirmed during stability testing. Read More
To defuse a growing scandal, Valeant Pharmaceuticals has cut ties with a mail-order pharmacy accused of pushing expensive drugs on pharmaceutical buyers. Read More
Warner Chilcott has agreed to pay $125 million to settle charges that it paid kickbacks to physicians to induce them to prescribe seven drugs, and the company’s former president was charged with conspiring to pay the kickbacks, the Department of Justice announced Thursday. Read More